Columbia University

Authors from various institutions collaborated on study conception, data collection, analysis, and manuscript drafting, focusing on tuberculosis research.

CytoDyn appoints Dr. Melissa Palmer as Lead Consultant in Hepatology to drive research on leronlimab for liver conditions like MASH and fibrosis. Follow-up studies with SMC Laboratories aim to confirm fibrosis reversal observed in previous studies, with results expected in early 2025.

IDE397, a MAT2A inhibitor, demonstrated antitumor activity and a manageable safety profile in MTAP-deletion urothelial cancer and NSCLC patients, with 33% achieving a confirmed overall response at the 30 mg RP2D. The study also showed a 93% disease control rate and 81% ctDNA molecular response rate, supporting further combination therapy development.

IDE397, a MAT2A inhibitor, showed 33% ORR and 93% DCR in NSCLC and urothelial cancer patients with MTAP deletions, with no treatment-related discontinuations. Plans for combination studies with sacituzumab govitecan-hziy and AMG 193 are underway.

Ideaya Biosciences presents phase 1 expansion data for IDE397, a potential first-in-class MAT2A inhibitor, in MTAP-deletion urothelial cancer and non-small cell lung cancer at ENA 2024, showing clinical efficacy and a manageable safety profile. The company plans to advance IDE397 as a monotherapy and in combinations, including with Trodelvy in urothelial cancer and AMG 193 in NSCLC.

GeneDx's GUARDIAN study, published in JAMA, found 3.7% of 4,000 newborns screened positive for genetic conditions undetectable by standard methods, including 120 with confirmed disorders not in traditional panels. The study screens for 255 conditions, 156 with established treatments, supported by Columbia University, NewYork-Presbyterian, and others, now expanded to 13,000 newborns and 446 genes. Similar studies are underway in the UK.

Long-term exposure to low levels of arsenic in drinking water increases heart disease risk, even below federal limit of 10 ug/L, according to a study in Environmental Health Perspectives. Researchers from Columbia University suggest more research is needed and advocate for stricter regulatory standards.

Raoul Kopelman, a pioneering researcher in nanoscience, focused on the space between atoms and molecules, leading to breakthroughs in precision medicine. Despite initial resistance to the term 'nano,' it later gained acceptance. Kopelman mentored numerous students, including Nobel laureates, and his work continues to influence interdisciplinary research.

MTX110 shows promising PFS and OS in Phase 1 study for recurrent glioblastoma, outperforming historic norms. The CED technology delivers high drug concentrations directly to tumors, potentially reducing side effects and improving survival.

MTX110 shows promising survival outcomes in recurrent glioblastoma, with patients achieving 12-13 months OS and 6-12 months PFS, using a novel CED delivery system.